News | May 30, 2024
Valent BioSciences opens new addition at Melnik and Shafer Biorational Research Center
Greg was also central to the planning, design, and construction of this facility
Greg was also central to the planning, design, and construction of this facility
Largest investment in active pharmaceutical ingredient manufacturing of synthetic medicines in U.S. history
Advancing IGC-AD1 Toward Commercialization as a Treatment for Agitation in Alzheimer's
The new 10-year contract will focus on strengthening the partnership for continued transformative innovation for patients
Through its rare kidney disease portfolio, Novartis is committed to exploring a range of treatment options with different modes of action to slow IgAN progression
The combined entity will enable us to better serve the needs of patients, healthcare professionals and our customers around the world
Establishing Asymchem’s first manufacturing footprint in Europe
Additional data from APPRAISE ATP trial reinforce modular therapy approach
At the recommended Phase 3 dose of 200 mg vepdegestrant in combination with palbociclib, patients achieved a median progression-free survival of 13.9 months
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
Subscribe To Our Newsletter & Stay Updated
